- Gaucher Disease
- Accession Number
- Not Available
Drug Drug Description Imiglucerase A form of recombinant human beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease. Alglucerase A form of recombinant beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease. Miglustat A glucosylceramide synthase inhibitor used for the management of mild to moderate type I Gaucher disease for patients who are not candidates for whole enzyme replacement. Taliglucerase alfa A hydrolytic lysosomal glucocerebroside specific enzyme, used for long term enzyme replacement therapy in patients with Type 1 Gaucher disease. Eliglustat A glucosylceramide synthase used to treat type 1 Gaucher disease in patients who are CYP2D6 extensive, intermediate, or poor metabolizers, based on the FDA-approved test.
- Drugs & Drug Targets
Drug Target Type Imiglucerase Glucocerebroside target Alglucerase Glucocerebroside target Miglustat Ceramide glucosyltransferase target Taliglucerase alfa Glucocerebroside target Eliglustat Ceramide glucosyltransferase target Eliglustat Cytochrome P450 2D6 enzyme Eliglustat Cytochrome P450 3A4 enzyme Eliglustat P-glycoprotein 1 transporter